Alteration of the HIF-1alfa/VEGF Signalling Pathway and Disruption of the Cell Cycle by Second Generation Carbosilan Dendrimers

Current therapies against prostate cancer (PCa) disease, such as surgery, radiotherapy, or in last term chemical castration by androgen deprivation, have led to significant reduction of the incidence of PCa throughout the world. Worse prognosis found in those patients which exhibit castration resist...

Descripción completa

Detalles Bibliográficos
Autores: Barrios Gumiel, Óscar|||0000-0002-1862-9793, Sánchez Gómez, Belén|||0000-0003-0971-1522, Rodríguez Prieto, Tamara|||0000-0002-3764-7217, Cano Sierra, Jesús|||0000-0002-6643-7534, Bort Bueno, Alicia Carmen|||0000-0003-1490-5823, Gómez Ramírez, Rafael|||0000-0001-6448-2414, Díaz-Laviada Marturet, Inés Cecilia|||0000-0001-9704-4373
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universidad de Alcalá (UAH)
Repositorio:e_Buah Biblioteca Digital Universidad de Alcalá
Idioma:inglés
OAI Identifier:oai:ebuah.uah.es:10017/59982
Acceso en línea:http://hdl.handle.net/10017/59982
https://dx.doi.org/10.1021/acs.biomac.2c00899
Access Level:acceso abierto
Palabra clave:NHC
carbosilane
dendrimer
imidazolium, ruthenium
prostate cancer
Química
Chemistry
Descripción
Sumario:Current therapies against prostate cancer (PCa) disease, such as surgery, radiotherapy, or in last term chemical castration by androgen deprivation, have led to significant reduction of the incidence of PCa throughout the world. Worse prognosis found in those patients which exhibit castration resistance, relapsing into the disease with e v e n greater aggressiveness. Hypoxia cancer cell adaption has been observed to be closely connected to fatal prognostic tumor features. Therefore, hypoxia adaptive mechanisms of cancer cells have attracted large interest as a relev a n t biological target for treatment-resistant patients. Dendrimer s have been established as a promising nanotechnological tool owing to their beneficial physicochemical features such as multivalency and monodispersity. Herein, we have completed a thorough study to better understand the effect wit h i n the cel l of the already published ruthenium(II)-N-heterocyclic carbene metallodendrimer (G2Ru) that was able to drastically reduce HIF-1 alpha stabilization and exhibited antiproliferative capabi l i t y against androgen-sensitive (LNCaP) and androgen-resistant prostate cancer cells (LNFLU) in vitro. G2Ru, as well as its cationic imidazol i u m precursor (G2P), displayed scaven g i n g properties against intracellula r and externa l l y stimulated ROS levels, which would presumably hinder the stabilization of HIF-1 alpha by prolyl hydroxylase (PHD) inhibition. Furthermore, these dendrimers have shown considerably beneficial properties against tumor progression capabi l i t y in terms of apoptosis, cell cycle, CSCs expression, and epithelial phenotype promotion. Taken all together, in this study we could demonstrate the extraordinary anticancer properties of NHC-based carbosilane dendrimers against androgen-resistant prostate cancer cells in vitro